CN110396539A - 用于检测高血压用药相关基因多态性的试剂盒和方法 - Google Patents
用于检测高血压用药相关基因多态性的试剂盒和方法 Download PDFInfo
- Publication number
- CN110396539A CN110396539A CN201910360574.2A CN201910360574A CN110396539A CN 110396539 A CN110396539 A CN 110396539A CN 201910360574 A CN201910360574 A CN 201910360574A CN 110396539 A CN110396539 A CN 110396539A
- Authority
- CN
- China
- Prior art keywords
- seq
- hypertension
- kit
- primer
- primer sets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 229940079593 drug Drugs 0.000 title claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 21
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 7
- 238000007689 inspection Methods 0.000 claims abstract description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 5
- 230000000702 anti-platelet effect Effects 0.000 claims abstract description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims abstract description 4
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002478 aldosterone Drugs 0.000 claims abstract description 4
- 108020004414 DNA Proteins 0.000 claims description 17
- 239000011324 bead Substances 0.000 claims description 16
- 238000012163 sequencing technique Methods 0.000 claims description 16
- 239000002220 antihypertensive agent Substances 0.000 claims description 7
- 229940127088 antihypertensive drug Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 5
- 229940097320 beta blocking agent Drugs 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 229940030606 diuretics Drugs 0.000 claims description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims description 4
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 4
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 4
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- -1 ockers Substances 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 238000012797 qualification Methods 0.000 claims description 3
- 102100038362 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 Human genes 0.000 claims description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims description 2
- KFVINGKPXQSPNP-UHFFFAOYSA-N 4-amino-2-[2-(diethylamino)ethyl]-n-propanoylbenzamide Chemical compound CCN(CC)CCC1=CC(N)=CC=C1C(=O)NC(=O)CC KFVINGKPXQSPNP-UHFFFAOYSA-N 0.000 claims description 2
- 102100027451 4-hydroxybenzoate polyprenyltransferase, mitochondrial Human genes 0.000 claims description 2
- 102100026400 ADP/ATP translocase 4 Human genes 0.000 claims description 2
- 102000017909 ADRA1A Human genes 0.000 claims description 2
- 102000017906 ADRA2A Human genes 0.000 claims description 2
- 102000017904 ADRA2C Human genes 0.000 claims description 2
- 102000017920 ADRB1 Human genes 0.000 claims description 2
- 102000017919 ADRB2 Human genes 0.000 claims description 2
- 101150037123 APOE gene Proteins 0.000 claims description 2
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 claims description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 2
- 102100034033 Alpha-adducin Human genes 0.000 claims description 2
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 claims description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 2
- 102100036811 Ankyrin repeat and fibronectin type-III domain-containing protein 1 Human genes 0.000 claims description 2
- 102100040197 Apolipoprotein A-V Human genes 0.000 claims description 2
- 108010061118 Apolipoprotein A-V Proteins 0.000 claims description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 2
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 2
- 102000017916 BDKRB1 Human genes 0.000 claims description 2
- 108060003359 BDKRB1 Proteins 0.000 claims description 2
- 102000017915 BDKRB2 Human genes 0.000 claims description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims description 2
- 102000014814 CACNA1C Human genes 0.000 claims description 2
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 claims description 2
- 102100023074 Calcium-activated potassium channel subunit beta-1 Human genes 0.000 claims description 2
- 102100033088 Calcium/calmodulin-dependent protein kinase type 1D Human genes 0.000 claims description 2
- 102100038930 Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein Human genes 0.000 claims description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 2
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims description 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims description 2
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 claims description 2
- 102100024902 Cytochrome P450 4F2 Human genes 0.000 claims description 2
- 102100036238 Dihydropyrimidinase Human genes 0.000 claims description 2
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 claims description 2
- 102100033902 Endothelin-1 Human genes 0.000 claims description 2
- 102000013339 FBXL17 Human genes 0.000 claims description 2
- 101150000662 FBXL17 gene Proteins 0.000 claims description 2
- 102100023734 G protein-coupled receptor kinase 4 Human genes 0.000 claims description 2
- 108010038179 G-protein beta3 subunit Proteins 0.000 claims description 2
- 102100035346 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 Human genes 0.000 claims description 2
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims description 2
- 101000605591 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 Proteins 0.000 claims description 2
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims description 2
- 101000725614 Homo sapiens 4-hydroxybenzoate polyprenyltransferase, mitochondrial Proteins 0.000 claims description 2
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 claims description 2
- 101000944272 Homo sapiens ATP-sensitive inward rectifier potassium channel 1 Proteins 0.000 claims description 2
- 101000689685 Homo sapiens Alpha-1A adrenergic receptor Proteins 0.000 claims description 2
- 101000689696 Homo sapiens Alpha-1D adrenergic receptor Proteins 0.000 claims description 2
- 101000756842 Homo sapiens Alpha-2A adrenergic receptor Proteins 0.000 claims description 2
- 101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 claims description 2
- 101000799076 Homo sapiens Alpha-adducin Proteins 0.000 claims description 2
- 101000928336 Homo sapiens Ankyrin repeat and fibronectin type-III domain-containing protein 1 Proteins 0.000 claims description 2
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 claims description 2
- 101000695703 Homo sapiens B2 bradykinin receptor Proteins 0.000 claims description 2
- 101000892264 Homo sapiens Beta-1 adrenergic receptor Proteins 0.000 claims description 2
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 claims description 2
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 claims description 2
- 101001049849 Homo sapiens Calcium-activated potassium channel subunit beta-1 Proteins 0.000 claims description 2
- 101000944258 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1D Proteins 0.000 claims description 2
- 101000741259 Homo sapiens Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein Proteins 0.000 claims description 2
- 101000909122 Homo sapiens Cytochrome P450 4F2 Proteins 0.000 claims description 2
- 101000930818 Homo sapiens Dihydropyrimidinase Proteins 0.000 claims description 2
- 101001023703 Homo sapiens E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 claims description 2
- 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 claims description 2
- 101000829481 Homo sapiens G protein-coupled receptor kinase 4 Proteins 0.000 claims description 2
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims description 2
- 101000839020 Homo sapiens Hydroxymethylglutaryl-CoA synthase, mitochondrial Proteins 0.000 claims description 2
- 101001006794 Homo sapiens Kinesin-like protein KIF6 Proteins 0.000 claims description 2
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 claims description 2
- 101000978210 Homo sapiens Leukotriene C4 synthase Proteins 0.000 claims description 2
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 claims description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims description 2
- 101001098256 Homo sapiens Lysophospholipase Proteins 0.000 claims description 2
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 2
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 claims description 2
- 101000615613 Homo sapiens Mineralocorticoid receptor Proteins 0.000 claims description 2
- 101000797269 Homo sapiens N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) Proteins 0.000 claims description 2
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 claims description 2
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 claims description 2
- 101000978730 Homo sapiens Nephrin Proteins 0.000 claims description 2
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims description 2
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 claims description 2
- 101000583225 Homo sapiens Pleckstrin homology domain-containing family H member 2 Proteins 0.000 claims description 2
- 101001002235 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 2 Proteins 0.000 claims description 2
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 claims description 2
- 101001069595 Homo sapiens Probable G-protein coupled receptor 83 Proteins 0.000 claims description 2
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 claims description 2
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 claims description 2
- 101001034347 Homo sapiens Protein MFI Proteins 0.000 claims description 2
- 101000928406 Homo sapiens Protein diaphanous homolog 3 Proteins 0.000 claims description 2
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 claims description 2
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 claims description 2
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 claims description 2
- 101000890554 Homo sapiens Retinal dehydrogenase 2 Proteins 0.000 claims description 2
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 claims description 2
- 101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 claims description 2
- 101000835995 Homo sapiens Slit homolog 1 protein Proteins 0.000 claims description 2
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 claims description 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims description 2
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims description 2
- 101000690425 Homo sapiens Type-1 angiotensin II receptor Proteins 0.000 claims description 2
- 101000672037 Homo sapiens UDP-glucose:glycoprotein glucosyltransferase 2 Proteins 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 101000621945 Homo sapiens Vitamin K epoxide reductase complex subunit 1 Proteins 0.000 claims description 2
- 101000742236 Homo sapiens Vitamin K-dependent gamma-carboxylase Proteins 0.000 claims description 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims description 2
- 101000626697 Homo sapiens YEATS domain-containing protein 4 Proteins 0.000 claims description 2
- 101000723898 Homo sapiens Zinc finger matrin-type protein 4 Proteins 0.000 claims description 2
- 102100028889 Hydroxymethylglutaryl-CoA synthase, mitochondrial Human genes 0.000 claims description 2
- 102100039884 Integrin-linked kinase-associated serine/threonine phosphatase 2C Human genes 0.000 claims description 2
- 101710160759 Integrin-linked kinase-associated serine/threonine phosphatase 2C Proteins 0.000 claims description 2
- 102000017786 KCNJ1 Human genes 0.000 claims description 2
- 102100027927 Kinesin-like protein KIF6 Human genes 0.000 claims description 2
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 claims description 2
- 102100023758 Leukotriene C4 synthase Human genes 0.000 claims description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 2
- 102100037611 Lysophospholipase Human genes 0.000 claims description 2
- 102100033320 Lysosomal Pro-X carboxypeptidase Human genes 0.000 claims description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 102000056548 Member 3 Solute Carrier Family 12 Human genes 0.000 claims description 2
- 102100031347 Metallothionein-2 Human genes 0.000 claims description 2
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 2
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 claims description 2
- 102100021316 Mineralocorticoid receptor Human genes 0.000 claims description 2
- 102100032946 N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) Human genes 0.000 claims description 2
- 102100031893 Nanos homolog 3 Human genes 0.000 claims description 2
- 102100034296 Natriuretic peptides A Human genes 0.000 claims description 2
- 102100023195 Nephrin Human genes 0.000 claims description 2
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 claims description 2
- 102100030360 Pleckstrin homology domain-containing family H member 2 Human genes 0.000 claims description 2
- 102100020950 Polypeptide N-acetylgalactosaminyltransferase 2 Human genes 0.000 claims description 2
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims description 2
- 102100033865 Probable G-protein coupled receptor 83 Human genes 0.000 claims description 2
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 claims description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 2
- 102100039641 Protein MFI Human genes 0.000 claims description 2
- 102100036468 Protein diaphanous homolog 3 Human genes 0.000 claims description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 claims description 2
- 102100024923 Protein kinase C beta type Human genes 0.000 claims description 2
- 101000629598 Rattus norvegicus Sterol regulatory element-binding protein 1 Proteins 0.000 claims description 2
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 claims description 2
- 102100040070 Retinal dehydrogenase 2 Human genes 0.000 claims description 2
- 108091006623 SLC12A3 Proteins 0.000 claims description 2
- 108091006583 SLC14A2 Proteins 0.000 claims description 2
- 108091006461 SLC25A31 Proteins 0.000 claims description 2
- 108091006731 SLCO1B1 Proteins 0.000 claims description 2
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 claims description 2
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 claims description 2
- 102100025490 Slit homolog 1 protein Human genes 0.000 claims description 2
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 claims description 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 2
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims description 2
- 102100026803 Type-1 angiotensin II receptor Human genes 0.000 claims description 2
- 102100040361 UDP-glucose:glycoprotein glucosyltransferase 2 Human genes 0.000 claims description 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 claims description 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 claims description 2
- 102100031085 Urea transporter 2 Human genes 0.000 claims description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 2
- 102100021164 Vasodilator-stimulated phosphoprotein Human genes 0.000 claims description 2
- 102100023485 Vitamin K epoxide reductase complex subunit 1 Human genes 0.000 claims description 2
- 102100038182 Vitamin K-dependent gamma-carboxylase Human genes 0.000 claims description 2
- 102100024780 YEATS domain-containing protein 4 Human genes 0.000 claims description 2
- 102100028433 Zinc finger matrin-type protein 4 Human genes 0.000 claims description 2
- 102000004311 liver X receptors Human genes 0.000 claims description 2
- 108090000865 liver X receptors Proteins 0.000 claims description 2
- 108010057284 lysosomal Pro-X carboxypeptidase Proteins 0.000 claims description 2
- SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 claims description 2
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 13
- 238000007403 mPCR Methods 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000013461 design Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000001631 hypertensive effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 101150119038 ABCB1 gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 102220090100 rs1045642 Human genes 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102200026593 rs1065852 Human genes 0.000 description 1
- 102200026617 rs1135840 Human genes 0.000 description 1
- 102200012755 rs2032582 Human genes 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于检测高血压用药相关基因多态性的引物组、试剂盒以及检测方法,引物组选自SEQ ID NO.1~SEQ ID NO.360核苷酸序列。本发明提供的引物组在多重PCR捕获后,可直接进行一轮PCR加接头;采用本发明的引物组和试剂盒不但操作简单,减少了实验步骤和检验;而且更进一步的降低DNA文库构建的耗材与人力成本;本发明的180对引物所对应的基因位点可指导的用药种类包含高血压治疗六大类高血压常用药,及高血压高并发症药物:抗凝、抗血小板、降糖、醛固酮、他汀类等常用药物,可以为初诊高血压、H型高血压、难治性高血压、高血压并动脉粥样硬化等并发症的人群治疗方案的选择提供指导,使患者尽早得到有效的治疗。
Description
技术领域
本发明涉及基因检测技术领域,尤其是一种用于检测高血压用药相关基因多态性的试剂盒和方法。
背景技术
高血压作为心脑血管病最重要的危险因素,也是我国患病率较高、致残率较高及疾病负担较重的慢性疾病。2016年国家卫生计生委发布的数据显示:我国18岁及以上成人高血压患病率为25.2%,流行态势严重。其主要并发症如卒中、心肌梗死、心力衰竭及慢性肾脏病等疾病,致残致死率高,严重消耗医疗和社会资源,给家庭和社会造成沉重负担,已成为我国一项重要的公共卫生问题。
目前临床上药物治疗是控制血压最有效的措施。药物基因组学研究表明,携带不同基因型的患者在药物吸收、转运、代谢、效应及清除作用过程中可能呈现反应的程度不同。通过检测药物代谢酶和药物靶点基因,可指导临床医生对特定患者选择合适的降压药物和给药剂量,提高降压药物的有效性和安全性。
高血压治疗药物种类多样,常用的有利尿剂、钙离子拮抗剂、血管紧张素转换酶抑制剂、β受体阻滞剂、血管紧张素II受体拮抗剂等。且高血压患者往往伴随着心脑血管疾病,需要联合应用调脂药物、抗炎药物、抗凝药物。但市场上的产品只针对一类或某几类甚至一种降压药物,对于初诊高血压患者、难治性高血压患者、H型高血压患者、高血压合并动脉粥样硬化等患者不利于合理进行联合用药指导。
在基因检测实现的技术方面,目前用于高血压基因多态性检测的技术一般有:(1)飞行时间质谱技术(2)Taqman探针法(3)Sanger测序法。其中,飞行质谱技术通过MALDI-TOFMS技术根据待检测样本终产物的质荷比(m/z)差异实现检测,灵敏度高且每个反应孔可实现多重反应,无需荧光标记性价比较高;但检测通量较低,且主要应用于检测已知SNP突变,对插入、缺失等突变不完全适用。Taqman探针法同时综合了5’端核酸酶活性和荧光等技术,通过对荧光信号的检测判断样本的基因型,灵敏度高,分型准确,操作简便快捷;但该方法通量不高,只能检测已知突变位点,主要适于对少量位点、大样本进行分型。Sanger测序基于双脱氧核糖核酸(ddNTP)末端终止法,测序长度较长,可发现新的变异位点;但灵敏度不高,对试剂和仪器有特殊要求,速度慢、通量低。
相比于以上技术,下一代测序技术(又称高通量测序或第二代测序技术)一次可对几十万到几百万条DNA进行测序,产生数G数据,广泛应用于基因组重测序、De novo测序、外显子测序、转录组测序以及宏基因组测序等测序技术,并结合生物信息学技术使其在疾病检测、分子育种、物种分析等方面发挥重要作用。且测序成本相对于第一代测序技术大幅下降,是目前正在高速发展中的技术。使用二代测序技术获取目标区域目前主要有两种方法:一种以PCR靶向富集为基础,另一种以探针杂交靶向富集为基础。探针法需要重复覆盖目的片段,因此价格较高;而多重PCR捕获的一般做法是PCR捕获、消化、加接头、纯化、PCR、纯化等一系列步骤,过程繁复操作周期长。
综上所述,目前市场上已有的与高血压用药基因检测相关的产品主要存在的问题有以下两点:
(1)高血压一般伴随着心脑血管疾病并发症,患者大部分需要联合用药,市场上的产品一般只针对高血压一种或多种高血压药物基因的检测,且不包含相关并发症的药物;
(2)虽然下一代测序技术成本大幅下降,但检测价格依然是制约其市场大规模应用的重要因素。其中,建库流程复杂,时间长,耗费人力物力是造成检测时间长,测序成本高的重要原因。
发明内容
本发明通过以下方面解决了上述技术问题:
首先,本发明涉及引物组,其选自SEQ ID NO.1~SEQ ID NO.360核苷酸序列。其中所述引物组,可以成对使用,所述引物对选自SEQ ID NO.1和SEQ ID NO.2;SEQ ID NO.3和SEQ ID NO.4;SEQ ID NO.5和SEQ ID NO.6;……SEQ ID NO.357和SEQ ID NO.358;以及SEQID NO.359和SEQ ID NO.360。
需要说明的是,本发明针对高血压患者常用降压药物、调脂药物、抗凝药物等药物相关基因位点设计上述基本扩增引物组,各条引物长度在为40~48b,难度在于180对引物的扩增条件保持一致,同时又能有效地扩增出目的片段,并且全部引物的Tm值控制在60℃,相差不超过1℃,扩增产物在100~350bp。其中,上游引物P1由两部分组成:一段23bp的固定序列(CCTACACGACGCTGTTCCGATCT)和一段17~25bp特异性片段扩增序列;下游引物同样由两部分组成:有一段22bp的固定序列(CAGACGTGTGCTCTTCCGATCT)和一段17~25bp特异性片段扩增序列,上游引物和下游引物形成多重PCR扩增引物组;上游引物和下游引物中的固定序列分别与特异性接头P3和P4中的3’端引物相同,多重PCR的扩增产物可直接通过与P3和P4接头引物混合反应,同时达到扩增文库和加标签的目的,以减少文库构建的操作步骤和时间,减少试剂成本、人力成本。
本发明还涉及用于检测高血压用药相关基因多态性的试剂盒,其包含上述的引物组。
在一些优选实施方案中,所述相关基因包括但不限于ABCB1、ABCC4、ABCG2、ACE、ACE2、ACY3、ADD1、ADRA1A、ADRA2A、ADRA2C、ADRB1、ADRB2、AGT、AGTR1、ALDH1A2、ANKFN1、APOA5、APOB、APOE、BDKRB1、BDKRB2、C11orf65、CACNA1C、CALU、CAMK1D、CES1、COQ2、CSMD1、CYP2C9、CYP2C19、CYP2D6、CYP11B2、CYP3A4、CYP3A5、CYP4F2、DIAPH3、DOT1L、DPYS、EDN1、FBXL17、FTO、GALNT2、GGCX、GNB3、GP1BA、GPR83、GRK4、HMGCR、HMGCS2、ILKAP、KCNH2、KCNJ1、KCNMB1、KIF6、LDLR、LRRC15、LTC4S、MMP3、MTHFR、MTR、NEDD4L、NOS1AP、NOS3、NPHS1、NPPA、NR1H3、NR3C2、PLA2G4A、PLCD3、PLEKHH2、PRCP、PRKCA、PRKCB、PROX1、PTGS1、PTGS2、PTPRD、SLC12A3、SLC14A2、SLC25A31、SLCO1B1、SLIT1、STK39、TCF7L2、TET2、UGGT2、UGT1A1、VASP、VEGFA、VKORC1、WNK1、YEATS4、ZMAT4。
在一些优选实施方案中,所述药包括但不限于血管紧张素转化酶抑制剂、血管紧张素II受体拮抗剂、钙通道抑制剂、β受体阻滞剂、利尿剂、中枢性降压药六大类高血压常用药,以及高血压高并发症抗凝、抗血小板、降糖、醛固酮、他汀类常用药物。
在一些优选实施方案中,所述试剂盒还包括第二轮PCR通用引物P3和P4。
在一些优选实施方案中,所述P4的核苷酸序列如SEQ ID NO.362所示,P4中“NNNNNNNN”片段为Index标签序列,由dATP、dTTP、dCTP、dGTP任意排列形成。
此外,本发明还涉及用于检测高血压用药相关基因多态性的方法,包括如下步骤:
提取一种或多种样本的DNA;
使用上述的引物组以样本DNA为模板进行PCR扩增,得到第一轮扩增产物,然后进行第一次磁珠纯化,得到第一轮PCR产物;
第一轮PCR产物,加入第二轮PCR通用引物P3和P4,进行PCR扩增,然后进行第二次磁珠纯化,得到第二轮PCR产物,即样本的高血压用药相关基因的DNA文库;以及
对质检合格的DNA文库测序以确定样本中高血压用药相关基因的基因型。
综上所述,本发明的有益效果为:
1.本发明提供的引物组在多重PCR捕获后,可直接进行一轮PCR加接头;采用本发明的引物组和试剂盒不但操作简单,减少了实验步骤和检验;而且更进一步的降低DNA文库构建的试剂耗材成本与人力成本;
2.本发明的180对引物所对应的基因位点可指导的用药种类包含高血压治疗的血管紧张素转化酶抑制剂、血管紧张素II受体拮抗剂、钙通道抑制剂、β受体阻滞剂、利尿剂、中枢性降压药六大类高血压常用药,及高血压高并发症药物:抗凝、抗血小板、降糖、醛固酮、他汀类等常用药物,可以为患有难治性高血压、初诊高血压、H型高血压、高血压并动脉粥样硬化等并发症的人群治疗方案的选择提供指导,使患者尽早得到有效的治疗。
附图说明
图1为样本013256文库片段检测结果图,显示文库片段在294~493bp呈现多峰分布;
图2为样本031638文库片段检测结果图,显示文库片段在295~487bp呈多峰分布;
图3为样本043219文库片段检测结果图,显示文库片段在295~497bp呈多峰分布;
图4为三个样本各检测片段测序深度统计图,显示样本平均深度达2000x以上,各位点检测深度均达1000x以上,均一性较好;
图5为采用Sanger法验证ABCB1基因rs1045642位点杂合突变的结果图。
具体实施方式
在一些实施例中,本发明提供了一种多重PCR文库构建引物设计方法,包括如下步骤:
(1)设计第一轮PCR捕获引物,捕获基因组DNA的目的片段;具体的第一轮PCR引物包含上游引物P1和下游引物P2;
P1由P1-1和P1-2两部分组成,P2由P2-1和P2-2两部分组成,
P1-1和P2-1分别为P3和P4 5′到3′方向末端20-25个碱基,
设计P1-2和P2-2的步骤为:
Ⅰ.NCBI上确定目的位点序列;
Ⅱ.使用Primer 5引物设计软件设计出目的位点上游引物P1-2和下游引物P2-2;
Ⅲ.通过NCBI进行验证引物具有单一扩增产物;
(2)确定第二轮PCR通用引物P3、P4,P3和P4具体序列如下表1所示:
表1 P3和P4碱基序列
其中P4中的“NNNNNNNN”片段为Index,是一段由dATP、dTTP、dCTP、dGTP任意组成的寡核苷酸序列。
采用上述引物设计方法,对高血压用药相关基因的92个基因154个位点和CYP2D6全基因序列进行了引物设计,共设计引物180对。优选的,P1-1和P2-1分别为P3和P4 5′到3′方向末端22个碱基,P1和P2的具体序列如下表2所示:
表2引物对P1和P2的碱基序列
上述180对引物所对应的基因位点可指导的用药种类包含血管紧张素转化酶抑制剂、血管紧张素II受体拮抗剂、钙通道抑制剂、β受体阻滞剂、利尿剂、中枢性降压药六大类高血压常用药,及高血压高并发症抗凝、抗血小板、降糖、醛固酮、他汀类等常用药物。
为更好的说明本发明的目的、技术方案和优点,下面将结合附图和具体实施例对本发明作进一步说明。如无特别说明,本发明中的试剂均可以从市场或其它公开渠道获得;如无特别说明,本发明中的实验方法均为常规方法。
实施例1针对高血压用药相关基因多态性位点的引物设计
(1)确定第二轮PCR通用引物P3、P4,具体序列如表1中的SEQ ID NO.361和SEQ IDNO.362所示。
其中P4中的“NNNNNNNN”片段为Index,是一段由dATP、dTTP、dCTP、dGTP任意组成的寡核苷酸序列。
(2)设计第一轮PCR上游引物P1和下游引物P2;其中P1由P1-1和P1-2两部分组成,P2由P2-1和P2-2两部分组成。
P1-1和P2-1分别为P3和P4 5′到3′方向末端22个碱基,具体序列如下表3所示:
表3 P1-1和P2-1碱基序列
P1-1 | CTACACGACGCTCTTCCGATCT |
P2-1 | CAGACGTGTGCTCTTCCGATCT |
设计P1-2和P2-2,包括步骤为:
Ⅰ.NCBI上确定位点序列;
Ⅱ.使用Primer 5引物设计软件设计出上游引物P1-2和下游引物P2-2;
Ⅲ.通过NCBI进行验证引物具有单一扩增产物。
设计出P1-2和P2-2具体序列如下表4所示:
表4 P1-2和P2-2碱基序列
(3)综上所述,高血压用药相关基因多态性位点第一轮PCR上游引物P1和下游引物P2序列如表2中SEQ ID NO.1~SEQ ID NO.360所示。
实施例2文库构建
1.取三例临床抗凝血样本(样本编号分别为:013256、031638、043219),使用自配或商业化核酸提取试剂盒提取人类基因组DNA,使用NanoDrop 2000超微量紫外分光光度计进行检测A260/A280,Qubit定量样品浓度C(ng/μl)。A260/A280=1.7~1.9提取结果如下表5所示:
表5
样本编号 | 013256 | 031638 | 043219 |
C(ng/μl) | 19.4 | 27.1 | 23.1 |
A260/A280 | 1.82 | 1.81 | 1.76 |
2.第一轮多重PCR反应
使用实施例1中设计的多重引物工作液(其中含有如表2中SEQ ID NO.1~SEQ IDNO.360所示引物组)对样品及空白对照进行首轮扩增。
扩增体系如下表6所示:
表6扩增体系
Component | Reaction volume |
2×KAPA2G FastMultiplex Mix | 12.5μL |
10μM Forward Primers | 0.25μL |
10μM Reverse Primers | 0.25μL |
Template DNA | 100ng |
H<sub>2</sub>O | Up to 25μL |
反应程序如下表7所示:
表7扩增反应程序
3.第1轮PCR产物用Agencourt AMPure XP Beads纯化
3.1涡旋振荡AMPure XP Beads让其悬浮。
3.2加入25μl(1×)悬浮的Agencourt AMPure XP Beads到PCR反应液中(约50μl)。用涡旋振荡器混匀或用移液器至少上下吹打10次。
3.3室温放置5分钟。
3.4在微型离心机快速离心,将管放置于磁力架,以分离磁珠和上清液。当溶液澄清后(大约5分钟),去除上清。
3.5保持管在磁力架上,加入200μl新配的80%乙醇于管中,室温放置30秒,然后小心移除上清。
3.6重复步骤3.5
3.7对管短暂离心,将管放置于磁力架,打开管盖,风干5分钟。
3.8将管从磁力架取下,加入23μl无菌水,从磁珠上洗脱目的DNA。用涡旋振荡器充分混匀或用移液器上下吹打,室温放置2分钟。将管放回磁力架,等溶液澄清。
3.9转移20μl上清至新的PCR管,储存于-20度。
4.第2轮接头序列PCR反应
用第1轮磁珠纯化后的PCR产物为模板,确定好Index,进行第二轮PCR;
确定第二轮PCR通用引物P3、P4,具体序列如下表8所示:
表8具体的P3和P4碱基序列
扩增体系如下表9所示:
表9扩增体系
反应程序如下表10所示:
表10反应程序
5.第2轮Agencourt AMPure XP Beads磁珠纯化
5.1涡旋振荡AMPure XP Beads让其悬浮。
5.2加入25μl(1×)悬浮的Agencourt AMPure XP Beads到PCR反应液中(约50μl)。用涡旋振荡器混匀或用移液器至少上下吹打10次。
5.3室温放置5分钟。
5.4在微型离心机快速离心,将管放置于磁力架,以分离磁珠和上清液。当溶液澄清后(大约5分钟),去除上清。
5.5保持管在磁力架上,加入200μl新配的80%乙醇于管中,室温放置30秒,然后小心移除上清。
5.6重复步骤5.5
5.7对管短暂离心,将管放置于磁力架,打开管盖,风干5分钟。
5.8将管从磁力架取下,加入23μl无菌水,从磁珠上洗脱目的DNA。用涡旋振荡器充分混匀或用移液器上下吹打,室温放置2分钟。将管放回磁力架,等溶液澄清。
5.9转移20μl上清至新的PCR管,储存于-20度。
6.文库定量和质检
使用Qubit 3.0和Qsep100全自动核酸蛋白分析系统检测文库浓度及片段大小。三个样本文库片段分布检测结果参见图1~3;文库浓度在10ng/μl-20ng/μl,符合≥10ng/μl的要求;文库片段在300-500bp之间,呈现多峰现象。
7.对质检合格的文库使用MiSeq测序仪(Illumina)进行2X 300bp测序。
数据分析,以GRCh38为参考序列,样本测序深度在2000X以上,Q30>80%,覆盖率95%以上,符合质控要求。三个样本文库的测序深度检测结果参见图4。三个样本其中10个基因突变分析结果如下表11所示:
表11基因分型
基因 | SNP | 013256 | 031638 | 043219 |
ABCB1 | rs2032582 | W | M | M |
ACE | rs4646994 | H | H | W |
ADD1 | rs4961 | H | H | M |
ADRB1 | rs1801253 | M | M | H |
AGTR1 | rs5186 | W | W | W |
CYP2C9 | rs1057910 | W | H | W |
CYP2C19 | rs4244285 | H | H | H |
CYP2D6 | rs1065852 | H | M | M |
CYP2D6 | rs1135840 | H | M | M |
CYP2D6 | rs1058164 | H | M | M |
MTHFR | rs1801133 | W | W | H |
PRKCA | rs16960228 | W | W | W |
SLCO1B1 | rs4149056 | W | W | W |
注:“W”表示野生型,碱基序列与参考序列相同;“H”表示杂合型,一条染色体上的碱基序列与参考序列相同,一条不同;“M”表示突变型,两条染色体上的碱基序列与参考序列均不同。
上述检测结果采用Sanger测序法进行验证,以ABCB1基因rs1045642位点Sanger测序结果为例,结果如图5所示;验证结果与Miseq测序仪检测结果相同。
最后应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
SEQUENCE LISTING
<110> 广州海思医疗科技有限公司
<120> 用于检测高血压用药相关基因多态性的试剂盒和方法
<130> 2019
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 22
<212> DNA
<213> 人工序列
<400> 1
ctacacgacg ctcttccgat ct 22
<210> 2
<211> 22
<212> DNA
<213> 人工序列
<400> 2
cagacgtgtg ctcttccgat ct 22
Claims (8)
1.引物组,其选自SEQ ID NO.1~SEQ ID NO.360核苷酸序列。
2.权利要求1的引物组,其中,所述引物组是成对使用的,所述引物对选自:SEQ IDNO.1和SEQ ID NO.2;
SEQ ID NO.3和SEQ ID NO.4;
SEQ ID NO.5和SEQ ID NO.6;
……
SEQ ID NO.357和SEQ ID NO.358;以及
SEQ ID NO.359和SEQ ID NO.360。
3.用于检测高血压用药相关基因多态性的试剂盒,其包含权利要求1或2所述的引物组。
4.权利要求3的试剂盒,其中所述相关基因包括ABCB1、ABCC4、ABCG2、ACE、ACE2、ACY3、ADD1、ADRA1A、ADRA2A、ADRA2C、ADRB1、ADRB2、AGT、AGTR1、ALDH1A2、ANKFN1、APOA5、APOB、APOE、BDKRB1、BDKRB2、C11orf65、CACNA1C、CALU、CAMK1D、CES1、COQ2、CSMD1、CYP2C9、CYP2C19、CYP2D6、CYP11B2、CYP3A4、CYP3A5、CYP4F2、DIAPH3、DOT1L、DPYS、EDN1、FBXL17、FTO、GALNT2、GGCX、GNB3、GP1BA、GPR83、GRK4、HMGCR、HMGCS2、ILKAP、KCNH2、KCNJ1、KCNMB1、KIF6、LDLR、LRRC15、LTC4S、MMP3、MTHFR、MTR、NEDD4L、NOS1AP、NOS3、NPHS1、NPPA、NR1H3、NR3C2、PLA2G4A、PLCD3、PLEKHH2、PRCP、PRKCA、PRKCB、PROX1、PTGS1、PTGS2、PTPRD、SLC12A3、SLC14A2、SLC25A31、SLCO1B1、SLIT1、STK39、TCF7L2、TET2、UGGT2、UGT1A1、VASP、VEGFA、VKORC1、WNK1、YEATS4、ZMAT4。
5.权利要求3或4的试剂盒,其中所述药包括血管紧张素转化酶抑制剂、血管紧张素II受体拮抗剂、钙通道抑制剂、β受体阻滞剂、利尿剂、中枢性降压药六大类高血压常用药,以及高血压高并发症抗凝、抗血小板、降糖、醛固酮、他汀类常用药物。
6.权利要求3的试剂盒,其还包括第二轮PCR通用引物P3和P4。
7.权利要求6的试剂盒,其中所述P4的核苷酸序列如SEQ ID NO.362所示,P4中“NNNNNNNN”片段为Index标签序列,由dATP、dTTP、dCTP、dGTP任意排列形成。
8.用于检测高血压用药相关基因多态性的方法,包括如下步骤:
提取一种或多种样本的DNA;
使用权利要求1或2的引物组以样本DNA为模板进行PCR扩增,得到第一轮扩增产物,然后进行第一次磁珠纯化,得到第一轮PCR产物;
第一轮PCR产物,加入第二轮PCR通用引物P3和P4,进行PCR扩增,然后进行第二次磁珠纯化,得到第二轮PCR产物,即样本的高血压用药相关基因的DNA文库;以及
对质检合格的DNA文库测序以确定样本中高血压用药相关基因的基因型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910360574.2A CN110396539A (zh) | 2019-04-29 | 2019-04-29 | 用于检测高血压用药相关基因多态性的试剂盒和方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910360574.2A CN110396539A (zh) | 2019-04-29 | 2019-04-29 | 用于检测高血压用药相关基因多态性的试剂盒和方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110396539A true CN110396539A (zh) | 2019-11-01 |
Family
ID=68323016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910360574.2A Pending CN110396539A (zh) | 2019-04-29 | 2019-04-29 | 用于检测高血压用药相关基因多态性的试剂盒和方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110396539A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111154861A (zh) * | 2020-01-17 | 2020-05-15 | 深圳会众生物技术有限公司 | 检测他汀类药物代谢基因多态性的引物及探针组合物、试剂盒、方法 |
CN112481372A (zh) * | 2020-12-10 | 2021-03-12 | 北京大学人民医院 | 用于检测慢性心力衰竭精准用药相关基因snp位点的引物及应用 |
CN113046432A (zh) * | 2021-03-18 | 2021-06-29 | 上海康黎诊断技术有限公司 | 一种用于指导人高血压用药的试剂盒 |
CN113215241A (zh) * | 2021-04-16 | 2021-08-06 | 武汉吉诺百客医学科技有限公司 | 一种用于心脑血管疾病风险预警的检测引物组及其应用 |
CN114032237A (zh) * | 2021-10-11 | 2022-02-11 | 哈尔滨医科大学 | 一种环状非编码RNA circSTK39及其在预防和治疗动脉粥样硬化中的应用 |
CN116814777A (zh) * | 2023-08-25 | 2023-09-29 | 北京宏微特斯生物科技有限公司 | 高血压用药指导相关基因多态位点的试剂盒及其使用方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060110751A1 (en) * | 2004-11-19 | 2006-05-25 | Oy Jurilab Ltd | Method and kit for detecting a risk of essential arterial hypertension |
CN106192021A (zh) * | 2016-08-02 | 2016-12-07 | 中国海洋大学 | 一种串联rad标签测序文库的构建方法 |
CN106755560A (zh) * | 2017-03-30 | 2017-05-31 | 德必碁生物科技(厦门)有限公司 | 一种多重荧光pcr法检测高血压用药基因多态性的试剂盒 |
CN108048561A (zh) * | 2018-01-29 | 2018-05-18 | 为朔医学数据科技(北京)有限公司 | 一种检测药物基因组学基因型的引物组、试剂盒及指导个性化用药的检测方法 |
CN108342466A (zh) * | 2018-05-04 | 2018-07-31 | 广州海思医疗科技有限公司 | 一种神经精神类药物相关基因的高通量测序方法及其应用 |
CN109082464A (zh) * | 2017-06-14 | 2018-12-25 | 合肥中科普瑞昇生物医药科技有限公司 | 一种检测高血压药物代谢相关基因的引物组和试剂盒 |
CN109182509A (zh) * | 2018-10-29 | 2019-01-11 | 广州金域医学检验集团股份有限公司 | 用于高血压相关药物基因多态性位点检测的引物组、试剂盒和方法 |
-
2019
- 2019-04-29 CN CN201910360574.2A patent/CN110396539A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060110751A1 (en) * | 2004-11-19 | 2006-05-25 | Oy Jurilab Ltd | Method and kit for detecting a risk of essential arterial hypertension |
CN106192021A (zh) * | 2016-08-02 | 2016-12-07 | 中国海洋大学 | 一种串联rad标签测序文库的构建方法 |
CN106755560A (zh) * | 2017-03-30 | 2017-05-31 | 德必碁生物科技(厦门)有限公司 | 一种多重荧光pcr法检测高血压用药基因多态性的试剂盒 |
CN109082464A (zh) * | 2017-06-14 | 2018-12-25 | 合肥中科普瑞昇生物医药科技有限公司 | 一种检测高血压药物代谢相关基因的引物组和试剂盒 |
CN108048561A (zh) * | 2018-01-29 | 2018-05-18 | 为朔医学数据科技(北京)有限公司 | 一种检测药物基因组学基因型的引物组、试剂盒及指导个性化用药的检测方法 |
CN108342466A (zh) * | 2018-05-04 | 2018-07-31 | 广州海思医疗科技有限公司 | 一种神经精神类药物相关基因的高通量测序方法及其应用 |
CN109182509A (zh) * | 2018-10-29 | 2019-01-11 | 广州金域医学检验集团股份有限公司 | 用于高血压相关药物基因多态性位点检测的引物组、试剂盒和方法 |
Non-Patent Citations (5)
Title |
---|
MURIELLE BOCHUD等: "Gene-environment interactions of selected pharmacogenes in arterial hypertension", 《EXPERT REVIEW OF CLINICAL PHARMACOLOGY》 * |
唐杨玲等: "高血压病药物治疗发展历程与展望", 《中华临床医师杂志》 * |
国家卫生计生委合理用药专家委员会等: "高血压合理用药指南(第2版)", 《 中国医学前沿杂志(电子版)》 * |
柴光德等: "抗高血压药物基因多态性研究进展", 《中华高血压杂志》 * |
许杜鹃等: "《全国普通高等医学院校药学类专业十三五规划教材 药学服务实务》", 31 January 2016 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111154861A (zh) * | 2020-01-17 | 2020-05-15 | 深圳会众生物技术有限公司 | 检测他汀类药物代谢基因多态性的引物及探针组合物、试剂盒、方法 |
CN112481372A (zh) * | 2020-12-10 | 2021-03-12 | 北京大学人民医院 | 用于检测慢性心力衰竭精准用药相关基因snp位点的引物及应用 |
CN112481372B (zh) * | 2020-12-10 | 2023-08-08 | 北京大学人民医院 | 用于检测慢性心力衰竭精准用药相关基因snp位点的引物及应用 |
CN113046432A (zh) * | 2021-03-18 | 2021-06-29 | 上海康黎诊断技术有限公司 | 一种用于指导人高血压用药的试剂盒 |
CN113215241A (zh) * | 2021-04-16 | 2021-08-06 | 武汉吉诺百客医学科技有限公司 | 一种用于心脑血管疾病风险预警的检测引物组及其应用 |
CN114032237A (zh) * | 2021-10-11 | 2022-02-11 | 哈尔滨医科大学 | 一种环状非编码RNA circSTK39及其在预防和治疗动脉粥样硬化中的应用 |
CN116814777A (zh) * | 2023-08-25 | 2023-09-29 | 北京宏微特斯生物科技有限公司 | 高血压用药指导相关基因多态位点的试剂盒及其使用方法 |
CN116814777B (zh) * | 2023-08-25 | 2023-12-12 | 北京宏微特斯生物科技有限公司 | 高血压用药指导相关基因多态位点的试剂盒及其使用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110396539A (zh) | 用于检测高血压用药相关基因多态性的试剂盒和方法 | |
JP6440658B2 (ja) | 薬理ゲノミクスバイオマーカーを発見するための方法 | |
JP2018514205A (ja) | 次世代の塩基配列分析技法を利用した臓器移植の拒否反応の予測方法 | |
CA2824431A1 (en) | Methods and systems for haplotype determination | |
CN108753954B (zh) | 痴呆相关基因的捕获探针组、试剂盒、文库构建方法和用途 | |
CN109576346A (zh) | 高通量测序文库的构建方法及其应用 | |
EP3607064A1 (en) | Method and kit for targeted enrichment of nucleic acids | |
CN106498035A (zh) | 一种用于高通量测序检测化疗药物基因snp变异文库的构建方法及其应用 | |
CN106498036A (zh) | 一种用于高通量测序检测的药物基因组snp变异文库的构建方法及其应用 | |
US20160208240A1 (en) | Ngs workflow | |
US20230366009A1 (en) | Simultaneous amplification of dna and rna from single cells | |
CN102766689B (zh) | 一种增加测序读长的测序方法 | |
CN102943107A (zh) | 分析生物样本的目标核酸序列的方法 | |
CN110846408A (zh) | 用于检测ttn基因突变的引物组合及其应用 | |
US20180291436A1 (en) | Nucleic acid capture method and kit | |
US20170137807A1 (en) | Improved ngs workflow | |
WO2018186947A1 (en) | Method and kit for targeted enrichment of nucleic acids | |
CN114875118B (zh) | 确定细胞谱系的方法、试剂盒和装置 | |
JPWO2007055255A1 (ja) | 複数の識別用核酸配列を増幅する方法 | |
US20210115503A1 (en) | Nucleic acid capture method | |
CN114085926A (zh) | Abcb1基因c3435t的snp位点多态性的引物和探针、试剂盒及检测方法 | |
CN113403377A (zh) | 药物和营养代谢能力检测snp位点引物组合物及应用 | |
CN111748621A (zh) | 一种检测肺癌相关41基因的探针库、试剂盒及其应用 | |
Amr et al. | Targeted hybrid capture for inherited disease panels | |
KR101532583B1 (ko) | 개인 유전체 snp 의 다중 분석 키트 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191101 |
|
RJ01 | Rejection of invention patent application after publication |